S-1/A: Cardiff Lexington Amends S-1 for Common Stock Offering

Cardiff Lexington Corporation filed an Amendment No. 2 to its S-1 Registration Statement, detailing the terms for a public offering of common stock and representative warrants.

Summary

• Cardiff Lexington Corporation filed Amendment No. 2 to its S-1 Registration Statement (File No. 333-292145) solely for the purpose of filing certain exhibits.
• The company is registering up to $7,245,000 of common stock, which includes $6,000,000 of Closing Shares on a firm commitment basis.
• An over-allotment option grants underwriters the right to purchase up to $900,000 of additional Option Shares.
• Up to $414,000 of Representatives Warrant Shares will be issued upon exercise of Common Stock Purchase Warrants granted to the underwriters.
• The Representatives Warrants will have an exercise price equal to 120% of the public offering price per share.
• Underwriters will receive an 8.0% discount to the public offering price per share.
• A non-accountable expense allowance equal to 1.0% of the gross proceeds will be paid to the Representative.
• A 180-day lock-up period applies to officers, directors, and holders of more than 5% of the company's common stock and equivalents, with specific exceptions for transfers.
• The company grants the Representative a right of first refusal for future public or private equity, equity-linked, or debt offerings (excluding commercial bank debt) for 12 months post-closing, with certain exceptions.

Sentiment

Score: 6

Explanation: The filing is largely procedural, detailing the mechanics of a planned public offering. While the capital raise itself is a positive step for growth, the terms (underwriter discounts, lock-up periods, right of first refusal) are standard for such transactions and do not inherently indicate exceptional positive or negative sentiment beyond the execution of a financing event.

Positives

• The company is proceeding with a public offering to raise capital, indicating a strategic move for growth or operational funding.
• The underwriting agreement includes a firm commitment for the purchase of Closing Shares, providing a degree of certainty for capital infusion.
• The company has reserved a sufficient number of authorized shares to cover the issuance of all shares related to the offering and warrants.

Negatives

• Underwriters will receive an 8.0% discount on the public offering price and a 1.0% non-accountable expense allowance, which reduces the net proceeds to the company.
• A 180-day lock-up period for officers, directors, and significant shareholders may limit their liquidity during that time.
• The grant of a 12-month right of first refusal to the Representative for future financings could potentially limit the company's flexibility in choosing financing partners or negotiating terms for subsequent capital raises.

Risks

• Potential for a material adverse effect on the legality, validity, or enforceability of any transaction document.
• Risk of a material adverse effect on the results of operations, assets, business, prospects, or financial condition of the company and its subsidiaries.
• Risk of a material adverse effect on the company's ability to perform its obligations under any transaction document.
• General economic, political, or financial conditions, industry-specific conditions, changes in laws or GAAP, acts of war, sabotage, terrorism, or natural disasters could disproportionately affect the company.
• Risk of litigation or regulatory actions that could materially adversely affect the business, operations, prospects, or financial condition.
• Risk of not maintaining the registration of the Common Stock under the Exchange Act.
• Risk of not maintaining the listing or quotation of the Common Stock on the Trading Market.
• Risk of security breaches or other compromises of the company's IT Systems and Data.
• Risk of non-compliance with applicable data privacy and security laws and regulations (e.g., GDPR, HIPAA, HITECH Act).
• Risk of non-compliance with federal, state, local, and foreign environmental laws.
• Risk of deficiencies in internal accounting controls.
• Risk of not being able to renew existing insurance coverage or obtain similar coverage without a significant increase in cost.
• Risk of potential liability under federal or state securities laws or claims of breach of fiduciary duty.
• Risk of the company's solvency, including its ability to pay debts as they mature, or having unreasonably small capital.
• Risk of the company becoming an investment company subject to registration under the Investment Company Act of 1940.
• Risk of non-compliance with the Foreign Corrupt Practices Act (FCPA).
• Risk of non-compliance with the Bank Holding Company Act of 1956 (BHCA).
• Risk of non-compliance with applicable money laundering laws.
• Risk of being deemed a U.S. real property holding corporation.

Future Outlook

The company intends to apply the net proceeds from the offering in a manner consistent with the 'Use of Proceeds' section in the Prospectus. It also plans to maintain the registration of its common stock under the Exchange Act for three years and retain a nationally recognized independent certified public accounting firm for at least three years.

Industry Context

This filing is a standard procedural step for a company undertaking a public offering, reflecting the regulatory requirements for capital market transactions. The terms, such as underwriter discounts, expense allowances, and lock-up periods, are customary within the investment banking industry for similar-sized offerings, indicating the company is progressing through a typical capital-raising process.

Corporate Governance

Related Party Transactions

• Loan Agreement and Convertible Promissory Note with L&H, Inc. (January 14, 2026)
• Loan Agreement and Convertible Promissory Note with Greentree Financial Group, Inc. (December 29, 2025)
• Loan Agreement and Convertible Promissory Note with James F. Sullivan (December 23, 2025)
• Loan Agreement and Convertible Promissory Note with Odile Viviane Kaye (December 22, 2025)
• Fixed Amount Settlement Promissory Note with GHS Investments, LLC (June 11, 2024)
• Securities Exchange Agreement and Security and Pledge Agreement with Leonite Capital LLC (May 13, 2024)
• Revolving Purchase and Security Agreement and Guaranty and Security Agreement with DML HC Series, LLC Series 308 (September 29, 2023)
• Securities Purchase Agreement, Guaranty, and Security Agreement with SILAC Insurance Company (June 1, 2021)
• Convertible Promissory Note with Greentree Financial Group, Inc. (January 24, 2017)
• Management Agreement with Nova Ortho and Spine, LLC and Dr. Marc D Brodsky, Michael Wycoki, Jr., PA and Dr. Kevin Fitzgerald (June 4, 2021)

Stakeholder Impact

• Shareholders: Potential dilution from the offering, but also potential for increased capital for company growth. Existing officers, directors, and significant shareholders (>5% holders) are subject to a 180-day lock-up period.
• Underwriters: Will receive an 8.0% discount on shares, a 1.0% non-accountable expense allowance, and a 12-month right of first refusal for certain future financings.
• Employees/Officers/Directors: Subject to a 180-day lock-up on their holdings of common stock and equivalents.

Next Steps

• The company will apply the net proceeds from the offering consistent with the 'Use of Proceeds' in the Prospectus.
• The company will use best efforts to maintain the registration of Common Stock under the Exchange Act for three years.
• The company will continue to retain a nationally recognized independent certified public accounting firm for at least three years.
• The company will apply to list all Closing Shares and Option Shares on the Trading Market concurrently with the Closing.
• The company will issue a press release disclosing the material terms of the Offering on the Execution Date.

Key Dates

Keywords

Cardiff Lexington Corporation, S-1/A filing, common stock offering, underwriting agreement, representative warrants, capital raise, public offering, SEC filing, equity financing, lock-up agreement, over-allotment option, financial markets, corporate governance, risk factors